{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:32:03Z","timestamp":1792290723398,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004507","name":"CSIR-Central Drug Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004507","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bcp.2025.116962","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T20:34:30Z","timestamp":1746736470000},"page":"116962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Fatty acid synthase inhibition offers protection against pressure-induced cardiac hypertrophy"],"prefix":"10.1016","volume":"238","author":[{"given":"Pragya","family":"Bharati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabha","family":"Burman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyapriya","family":"Mahapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baisakhi","family":"Moharana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Nilkanth","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaravelu","family":"Jagavelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-6024","authenticated-orcid":false,"given":"Kashif","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bcp.2025.116962_b0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","article-title":"Mechanisms of physiological and pathological cardiac hypertrophy","volume":"15","author":"Nakamura","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2025.116962_b0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1086\/679608","article-title":"Cardiac energy metabolic alterations in pressure overload\u2013induced left and right heart failure (2013 Grover Conference Series)","volume":"5","author":"Sankaralingam","year":"2015","journal-title":"Pulmonary Circulation"},{"issue":"2","key":"10.1016\/j.bcp.2025.116962_b0015","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3390\/ijms23020996","article-title":"Deranged myocardial fatty acid metabolism in heart failure","volume":"23","author":"Yamamoto","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2025.116962_b0020","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2174\/187152511797037583","article-title":"Up-regulation of the cardiac lipid metabolism at the onset of heart failure","volume":"9","author":"AbdAlla","year":"2011","journal-title":"Cardiovascular Hematological Agents in Medicinal Chemistry"},{"issue":"6","key":"10.1016\/j.bcp.2025.116962_b0025","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1074\/jbc.M115.702688","article-title":"Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice*","volume":"291","author":"Abd Alla","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"35","key":"10.1016\/j.bcp.2025.116962_b0030","doi-asserted-by":"crossref","first-page":"30949","DOI":"10.1074\/jbc.M111.230508","article-title":"Fatty acid synthase modulates homeostatic responses to myocardial stress","volume":"286","author":"Razani","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.116962_b0035","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.atherosclerosis.2017.06.001","article-title":"Cardiovascular disease and cancer: evidence for shared disease pathways and pharmacologic prevention","volume":"263","author":"Masoudkabir","year":"2017","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.bcp.2025.116962_b0040","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1111\/bph.13495","article-title":"Inhibition of fatty acid synthase is protective in pulmonary hypertension","volume":"173","author":"Singh","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116962_b0045","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ejphar.2017.09.042","article-title":"Fatty acid synthase modulates proliferation, metabolic functions and angiogenesis in hypoxic pulmonary artery endothelial cells","volume":"815","author":"Singh","year":"2017","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2025.116962_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.111569","article-title":"Involvement of fatty acid synthase in right ventricle dysfunction in pulmonary hypertension","volume":"383","author":"Singh","year":"2019","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.bcp.2025.116962_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2018.07.019","article-title":"Impairment of angiogenesis by fatty acid synthase inhibition involves mTOR malonylation","volume":"28","author":"Bruning","year":"2018","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bcp.2025.116962_b0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00204-022-03363-6","article-title":"Autophagy (but not metabolism) is a key event in mitoxantrone-induced cytotoxicity in differentiated AC16 cardiac cells","volume":"97","author":"Reis-Mendes","year":"2023","journal-title":"Arch. Toxicol."},{"issue":"7","key":"10.1016\/j.bcp.2025.116962_b0065","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.3390\/ijms22073620","article-title":"Metabolic interventions to prevent hypertrophy-induced alterations in contractile properties in vitro","volume":"22","author":"Geraets","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.116962_b0070","series-title":"Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor","first-page":"3019","author":"Zhang","year":"2017"},{"issue":"1","key":"10.1016\/j.bcp.2025.116962_b0075","first-page":"153","article-title":"Increased fatty acid synthase is a therapeutic target in mesothelioma","volume":"7","author":"Gabrielson","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.116962_b0080","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1007\/s12035-017-0754-5","article-title":"Angiotensin receptor blockade by inhibiting glial activation promotes hippocampal neurogenesis via activation of Wnt\/\u03b2-catenin signaling in hypertension","volume":"55","author":"Bhat","year":"2018","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.bcp.2025.116962_b0085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00395-023-01016-y","article-title":"Musashi-2 causes cardiac hypertrophy and heart failure by inducing mitochondrial dysfunction through destabilizing Cluh and Smyd1 mRNA","volume":"118","author":"Singh","year":"2023","journal-title":"Basic Res. Cardiol."},{"issue":"5","key":"10.1016\/j.bcp.2025.116962_b0090","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/15384047.2015.1026480","article-title":"Human UDP-Glucuronosyltransferases: Effects of altered expression in breast and pancreatic cancer cell lines","volume":"16","author":"Dates","year":"2015","journal-title":"Cancer Biology Therapy"},{"issue":"1","key":"10.1016\/j.bcp.2025.116962_b0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12035-022-03061-5","article-title":"Activation of Angiotensin-converting Enzyme 2 Protects Against Lipopolysaccharide-induced Glial Activation by Modulating Angiotensin-converting Enzyme 2\/Angiotensin (1\u20137)\/Mas Receptor Axis","volume":"60","author":"Tiwari","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2025.116962_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2024.103953","article-title":"Activation of angiotensin converting enzyme 2 promotes hippocampal neurogenesis via activation of Wnt\/\u03b2-catenin signaling in hypertension","volume":"130","author":"Tiwari","year":"2024","journal-title":"Molecular Cellular Neuroscience"},{"issue":"4","key":"10.1016\/j.bcp.2025.116962_b0105","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1161\/HYPERTENSIONAHA.120.15229","article-title":"Inhibition of mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK2) is protective in pulmonary hypertension","volume":"77","author":"Shafiq","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2025.116962_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2022.102156","article-title":"Pyrroloquinoline quinone (PQQ) improves pulmonary hypertension by regulating mitochondrial and metabolic functions","volume":"76","author":"Shafiq","year":"2022","journal-title":"Pulmonary Pharmacology Therapeutics"},{"issue":"5","key":"10.1016\/j.bcp.2025.116962_b0115","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.apsb.2020.10.007","article-title":"Energy metabolism disorders and potential therapeutic drugs in heart failure","volume":"11","author":"He","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.bcp.2025.116962_b0120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.15420\/cfr.2015.1.2.112","article-title":"Metabolic therapy in heart failure","volume":"1","author":"Lopatin","year":"2015","journal-title":"Card. Fail. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2025.116962_b0125","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1451676","article-title":"Inhibition of receptor interacting protein kinases attenuates cardiomyocyte hypertrophy induced by palmitic acid","volume":"2016","author":"Zhao","year":"2016","journal-title":"Oxidative Medicine Cellular Longevity"},{"issue":"3","key":"10.1016\/j.bcp.2025.116962_b0130","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/CIRCRESAHA.114.302022","article-title":"mTOR signaling in cardiac physiology and disease: Sciarretta, mTOR signaling in the cardiovascular system","volume":"114","author":"Sciarretta","year":"2014","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.bcp.2025.116962_b0135","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","article-title":"SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth","volume":"8","author":"Porstmann","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2025.116962_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13036-021-00276-3","article-title":"AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo","volume":"15","author":"Cha","year":"2021","journal-title":"J. Biol. Eng."},{"issue":"12","key":"10.1016\/j.bcp.2025.116962_b0145","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000057979.36322.88","article-title":"Rapamycin attenuates load-induced cardiac hypertrophy in mice","volume":"107","author":"Shioi","year":"2003","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.bcp.2025.116962_b0150","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1161\/CIRCULATIONAHA.111.060889","article-title":"Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure","volume":"125","author":"Chokshi","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.bcp.2025.116962_b0155","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1161\/CIRCHEARTFAILURE.112.966705","article-title":"Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction","volume":"5","author":"Mori","year":"2012","journal-title":"Circ. Heart Fail."},{"issue":"3","key":"10.1016\/j.bcp.2025.116962_b0160","first-page":"385","article-title":"Malonyl CoA decarboxylase inhibition improves cardiac function post-myocardial infarction. JACC: Basic to Translational","volume":"4","author":"Wang","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.bcp.2025.116962_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106038","article-title":"Mitochondrial dysfunction and mitochondrial therapies in heart failure","volume":"175","author":"Wu","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.bcp.2025.116962_b0170","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/CIRCRESAHA.111.255216","article-title":"Redox signaling in cardiac physiology and pathology","volume":"111","author":"Burgoyne","year":"2012","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.bcp.2025.116962_b0175","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.coph.2005.10.008","article-title":"NADPH oxidase and heart failure","volume":"6","author":"Murdoch","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"issue":"19","key":"10.1016\/j.bcp.2025.116962_b0180","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.0510444103","article-title":"Requirement of Rac1 in the development of cardiac hypertrophy","volume":"103","author":"Satoh","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2025.116962_b0185","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/abbs\/gmx102","article-title":"Alterations in NO\/ROS ratio and expression of Trx1 and Prdx2 in isoproterenol-induced cardiac hypertrophy","volume":"49","author":"Su","year":"2017","journal-title":"Acta Biochim. Biophy. Sin."},{"issue":"3","key":"10.1016\/j.bcp.2025.116962_b0190","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/cvr\/cvy217","article-title":"Choline ameliorates cardiac hypertrophy by regulating metabolic remodelling and UPRmt through SIRT3-AMPK pathway","volume":"115","author":"Xu","year":"2019","journal-title":"Cardiovasc. Res."},{"issue":"7","key":"10.1016\/j.bcp.2025.116962_b0195","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/cells12071042","article-title":"Palmitate-induced cardiac lipotoxicity is relieved by the redox-active motif of SELENOT through improving mitochondrial function and regulating metabolic state","volume":"12","author":"Rocca","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2025.116962_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12986-019-0356-5","article-title":"High-density lipoprotein ameliorates palmitic acid-induced lipotoxicity and oxidative dysfunction in H9c2 cardiomyoblast cells via ROS suppression","volume":"16","author":"Wu","year":"2019","journal-title":"Nutrition Metabolism"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225002242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225002242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:57:41Z","timestamp":1785499061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225002242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":40,"alternative-id":["S0006295225002242"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116962","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty acid synthase inhibition offers protection against pressure-induced cardiac hypertrophy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116962"}}